NDC 22840-0201-02: Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 10000 [BAU]/mL Solution, 10 mL Vial
This is a package of 10 mL of Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 10000 [BAU]/mL Solution from Greer Laboratories, Inc., first listed with the FDA Sep 1968 and currently FDA-listed. It is the main listing for this product, which comes in 3 package sizes.
NDC database record
One package, one record: these facts belong to NDC 22840-0201-2 alone.
- Record
- FDA NDC Directory package listing · Standardized allergenic
- Code segments
- 22840 labeler · 0201 product · 2 package
- Package marketed since
- Sep 15, 1968
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 2284002012 4
- FDA record last changed
- Oct 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 22840-0201-02 You're viewing this Main listing | 10 mL in 1 VIAL, MULTI-DOSE | 1968-09-15 | — | Active |
| 22840-0201-04 22840-0201-4 | 50 mL in 1 VIAL, MULTI-DOSE | 1968-09-15 | — | Active |
| 22840-0201-05 22840-0201-5 | 5 mL in 1 BOTTLE, DROPPER | 1968-09-15 | — | Active |
You're viewing one of 3 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 22840-0201-05?
What NDC number is used to bill for this package of Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 10000 [BAU]/mL Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Standardized Kentucky (June) Bluegrass Pollen 10000 [BAU]/mLthis 22840-0201-02 | Greer | 10 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 339NCG44TV
Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
-
UNII 8MDF5V39QO
A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Greer Laboratories, Inc. labeler code 22840
- Standardized Mite Mix Dermatophagoides farinae and Dermatophagoides pteronyssinus 5000 [AU]/mL; 5000 [AU]/mL Concentrate NDC 22840-0037-3
- Standardized Mite Dermatophagoides farinae 30000 [AU]/mL Concentrate NDC 22840-0038-6
- Standardized Mite Dermatophagoides pteronyssinus 30000 [AU]/mL Concentrate NDC 22840-0039-6
- Standardized Cat Hair Allergenic Extract Felis catus 5000 [BAU]/mL; 5000 [BAU]/mL Solution NDC 22840-0100-2
- Standardized Cat Hair Allergenic Extract Felis catus 10000 [BAU]/mL; 10000 [BAU]/mL Solution NDC 22840-0101-2
- Standardized Bermuda Grass Pollen Cynodon dactylon 10000 [BAU]/mL Solution NDC 22840-0200-2
- Standardized Kentucky (June) Bluegrass Pollen Poa pratensis 100000 [BAU]/mL Solution NDC 22840-0202-2
- Standardized Meadow Fescue Pollen Festuca elatior 10000 [BAU]/mL Solution NDC 22840-0203-2
- Standardized Meadow Fescue Pollen Festuca elatior 100000 [BAU]/mL Solution NDC 22840-0204-2
- Standardized Orchard Grass Pollen Dactylis glomerata 10000 [BAU]/mL Solution NDC 22840-0205-2
- Standardized Orchard Grass Pollen Dactylis glomerata 100000 [BAU]/mL Solution NDC 22840-0206-2
- Standardized Redtop Pollen Agrostis alba 10000 [BAU]/mL Solution NDC 22840-0207-2
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🚨 Boxed Warning ▾
FULL PRESCRIBING INFORMATION WARNING: SEVERE ALLERGIC REACTIONS Standardized Grass Pollen Allergenic Extracts can cause severe life-threatening systemic reactions, including anaphylaxis. (5.1) Do not administer Standardized Grass Pollen Allergenic Extracts to patients with severe, unstable, or uncontrolled asthma. (4) Observe patients in the office for at least 30 minutes following treatment.Emergency measures and personnel trained in their use must be available immediately in the event of a life-threatening reaction.
(5.1) Patients with extreme sensitivity, to Standardized Grass Pollen Allergenic Extracts, those on an accelerated immunotherapy build-up schedule, those switching to another allergenic lot, those receiving high doses of the Standardized Grass Pollen Allergenic Extracts, or those also exposed to similar allergens may be at increased risk of a severe allergic reaction. (5.1) Standardized Grass Pollen Allergenic Extracts may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
(5.1) Standardized Grass Pollen Allergenic Extracts may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta‑blockers. (5.2)
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE GREER Standardized Grass Pollen Allergenic Extracts are indicated for: Skin test diagnosis of patients with a clinical history of allergy to one or more of the following grass pollens: Bermuda, Kentucky Blue (June), Meadow Fescue, Orchard, Perennial Rye, Redtop, Sweet Vernal, Timothy. Immunotherapy for the reduction of grass pollen-induced allergic symptoms confirmed by positive skin test or by in vitro testing for pollen-specific IgE antibodies for Bermuda grass pollen, Kentucky Blue (June) grass pollen, Meadow Fescue grass pollen, Orchard grass pollen, Perennial Rye grass pollen, Redtop grass pollen, Sweet Vernal grass pollen, or Timothy grass pollen.
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For percutaneous, intradermal or subcutaneous use only. The extracts are diluted with sterile diluents when used for intradermal testing or subcutaneous immunotherapy. For percutaneous testing, the extracts are diluted with sterile diluents in patients expected to be at greater risk for systemic allergic reaction. Dosages vary by mode of administration and by individual response.
2.1Preparation for Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard solution if either of these conditions exist. The extracts are diluted with sterile diluents when used for percutaneous and intradermal testing, or for subcutaneous immunotherapy.
Undiluted 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrates are used for percutaneous testing. To prepare 10-fold dilutions for percutaneous testing in patients suspected to be at greater risk for systemic allergic reaction, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate. Proceed as shown in Table 1.
The 10-fold dilution series uses 0.5 milliliters of concentrate added to 4.5 milliliters of sterile 50% glycerin diluent. Subsequent dilutions are made in a similar manner. To prepare 10-fold dilutions for intradermal testing and immunotherapy, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate.
Proceed as shown in Table 1. The 10-fold dilution series uses 0.5 milliliters of concentrate added to 4.5 milliliters of sterile diluent (glycerin-free diluents for intradermal testing, glycerin-free or 10% glycerin-saline diluents for immunotherapy). Subsequent dilutions are made in a similar manner.
Table 1: 10-fold Dilution Series* Dilution Extract Milliliters of Diluent Dilution Strength (BAU/mL) Dilution Strength (BAU/mL 0 Concentrate 100,000 10,000 1 0.5 mL Concentrate 4.5 10,000 1,000 2 0.5 mL Dilution 1 4.5 1,000 100 3 0.5 mL Dilution 2 4.5 100 10 4 0.5 mL Dilution 3 4.5 10 1 5 0.5 mL Dilution 4 4.5 1 0.1 6 0.5 mL Dilution 5 4.5 0.1
0.01Undiluted 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrates are used for percutaneous testing. To prepare 5-fold dilutions for percutaneous testing in patients suspected to be at greater risk for systemic allergic reaction, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate. Proceed as shown in Table 2.
The 5-fold dilution series uses 1 milliliter of concentrate added to 4 milliliters of sterile 50% glycerin diluent. Subsequent dilutions are made in a similar manner. To prepare 5-fold dilutions for intradermal testing and immunotherapy, start with a 10,000 BAU/milliliter or 100,000 BAU/milliliter stock concentrate.
Proceed as shown in Table 2. The 5-fold dilution series uses 1 milliliter of concentrate added to 4 milliliters of sterile diluent (glycerin-free diluents for intradermal testing, glycerin-free or 10% glycerin-saline diluents for immunotherapy). Subsequent dilutions are made in a similar manner.
Table 2: 5-fold Dilution Series* Dilution Extract Milliliters of Diluent Dilution Strength (BAU/mL) Dilution Strength (BAU/mL) 0 Concentrate 100,000 10,000 1 1 mL Concentrate 4 20,000 2,000 2 1 mL Dilution 1 4 4,000 400 3 1 mL Dilution 2 4 800 80 4 1 mL Dilution 3 4 160 16 5 1 mL Dilution 4 4 32 3.2 6 1 mL Dilution 5 4 6.4 0.64
2.2Diagnostic Testing Diagnostic testing can be performed via percutaneous or intradermal administration of the Standardized Grass Pollen Allergenic Extracts. A positive skin test reaction should be interpreted in relation to the patient’s history and known exposure to the allergen. If a skin test with a grass pollen extract mixture elicits a positive reaction, then the single-species grass pollen extracts can be used to determine the degree of sensitivity to each individual grass species and to guide in the selection of extracts and their concentration for immunotherapy, i… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Standardized Bermuda Grass Pollen Allergenic Extract solution is available only at 10,000 Bioequivalent Allergy Units (BAU)/milliliter. Other Standardized Grass Pollen Allergenic Extract solutions are available as stock concentrates at 10,000 and 100,000 BAU/milliliter.
⛔ Contraindications ▾
4 CONTRAINDICATIONS Standardized Grass Pollen Allergenic Extracts are contraindicated in patients with: Severe, unstable or uncontrolled asthma History of any severe systemic allergic reaction or any severe local reaction to subcutaneous allergen immunotherapy
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS
5.1Serious Systemic Adverse Reactions Serious systemic adverse reactions have occurred following the administration of other allergenic extracts and may occur in individuals following the administration of Standardized Grass Pollen Allergenic Extracts in the following situations: Extreme sensitivity to grass pollen allergenic extracts Receipt of an accelerated immunotherapy build-up schedule (e.g., “rush” immunotherapy) Receipt of high doses of grass pollen allergenic extracts or concomitant exposure to similar environmental allergens Change from one allergenic lot to another allergenic lot High-risk patients have had fatal reactions.
Consider using more dilute preparations in patients suspected to be at greater risk of systemic allergic reaction [see Dosage and Administration (2.1)]. Administer Standardized Grass Pollen Allergenic Extracts in a healthcare setting under the supervision of a physician prepared to manage a severe systemic or a severe local allergic reaction. Observe patients in the office for at least 30 minutes following administration.
1
5.2Epinephrine Standardized Grass Pollen Allergenic Extracts may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. These products may not be suitable for patients who are taking medications that can potentiate or inhibit the effect of epinephrine.
These medications include: Βeta-adrenergic blockers : Patients taking beta-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis. Specifically, beta-adrenergic blockers antagonize the cardiostimulating and bronchodilating effects of epinephrine. Alpha-adrenergic blockers, ergot alkaloids : Patients taking alpha-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis.
Specifically, alpha-adrenergic blockers antagonize the vasoconstricting and hypertensive effects of epinephrine. Similarly, ergot alkaloids may reverse the pressor effects of epinephrine. Tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and certain antihistamines : The adverse effects of epinephrine may be potentiated in patients taking tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and the antihistamines chlorpheniramine, and diphenhydramine.
Cardiac glycosides, diuretics : Patients who receive epinephrine while taking cardiac glycosides or diuretics should be observed carefully for the development of cardiac arrhythmias.
5.3Cross-Reactions and Dose Sensitivity Since many grass species tend to cross-react, the total allergen content should be considered in determining the maximum maintenance dose of the mixture. Determine the initial dilution of allergenic extract, starting dose, and progression of dosage based on the patient’s history and results of skin tests [see Dosage and Administration (2.2)]. 2 Strongly positive skin tests can be indicators for potential systemic reactions.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The most common adverse reactions, occurring in 26 to 82% of all patients who receive subcutaneous immunotherapy are local adverse reactions at the injection site (e.g., erythema, itching, swelling, tenderness, pain). 1 Systemic adverse reactions, occurring in 7% of patients who receive subcutaneous immunotherapy, 3 include generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, and hypotension. These adverse reactions can be fatal.
1
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS
7.1Antihistamines Do not perform skin testing with allergenic extracts within 3 to 10 days of use of first-generation H 1 -histamine receptor blockers (e.g., clemastine, diphenhydramine) and second-generation antihistamines (e.g., loratadine, cetirizine). These products suppress histamine skin test reactions and could mask a positive response. 2
7.2Topical Corticosteroids and Topical Anesthetics Topical corticosteroids can suppress skin reactivity; therefore, discontinue use at the skin test site for 2 to 3 weeks before skin testing. Avoid use of topical local anesthetics at skin test sites as they can suppress flare responses. 2
7.3Tricyclic Antidepressants Tricyclic antidepressants can have potent antihistamine effects that can affect skin testing. If tricyclic medication has been recently discontinued, allow 7 to 14 days before initiating skin testing. 2
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. There are no human or animal data to establish the presence or absence of Standardized Grass Pollen Allergenic Extracts-associated risks during pregnancy.
8.2Lactation Risk Summary It is not known whether Standardized Grass Pollen Allergenic Extracts are present in human milk. Data are not available to assess the effects of these extracts on the breastfed child or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Standardized Grass Pollen Allergenic Extracts and any potential adverse effects on the breastfed child from the extracts or from the underlying maternal condition.
8.4Pediatric Use For use of these products in children younger than 5 years of age, consideration should be given to the patients’ ability to comply and cooperate with allergen immunotherapy and the potential for difficulty in communicating with the child regarding systemic reactions. 1
8.5Geriatric Use Data are not available to determine if subjects 65 years of age and older respond differently to allergen immunotherapy than younger subjects.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The skin test reaction results from interaction of the introduced allergen and allergen-specific IgE antibodies bound to mast cells, leading to mast cell degranulation and release of histamine, tryptase and other mediators, which results in the formation of the wheal and flare. The precise mechanisms of action of allergen immunotherapy are not known. Immunologic responses to immunotherapy include changes in allergen-specific IgE levels, allergen-specific IgG levels, and regulatory T cell responses.
1
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1How Supplied GREER Standardized Grass Pollen Allergenic Extracts and mixes are supplied as stock concentrates at 10,000 BAU/milliliter and 100,000 BAU/milliliter in 50% glycerin for use in percutaneous skin testing, intradermal testing, and subcutaneous immunotherapy. Standardized Grass Pollen Allergenic Extracts are labeled in BAU/milliliter and are provided in 5, 10, and 50 milliliter vials. Note, the total potency of mixes containing standardized grasses may be cumulative.
Standardized Bermuda Grass Pollen Allergenic Extract solution is available only at 10,000 BAU/milliliter. GREER Standardized Grass Pollen Allergenic Extracts and mixes are supplied as follows: Standardized Bermuda Grass Pollen (Cynodon dactylon) NDC Number Strength/Container 22840-0200-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0200-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0200-4 10,000 BAU/mL, 50 mL multiple-dose vials Standardized Bluegrass, Kentucky (June) Grass Pollen (Poa pratensis) NDC Number Strength/Container 22840-0201-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0201-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0201-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0202-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0202-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0202-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Meadow Fescue Grass Pollen (Festcua elatoir) NDC Number Strength/Container 22840-0203-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0203-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0203-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0204-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0204-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0204-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Orchard Grass Pollen (Dactylis glomerata) NDC Number Strength/Container 22840-0205-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0205-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0205-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0206-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0206-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0206-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Perennial Rye Grass Pollen (Lolium perenne) NDC Number Strength/Container 22840-0209-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0209-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0209-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0210-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0210-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0210-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Redtop Grass Pollen (Agrostis alba) NDC Number Strength/Container 22840-0207-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0207-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0207-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0208-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0208-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0208-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Sweet Vernal Grass Pollen (Anthoxanthum odoratum) NDC Number Strength/Container 22840-0211-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0211-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0211-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0212-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0212-2 100,000 BAU/mL, 10 mL multiple-dose vials 22840-0212-4 100,000 BAU/mL, 50 mL multiple-dose vials Standardized Timothy Grass Pollen (Phelum pratense) NDC Number Strength/Container 22840-0213-5 10,000 BAU/mL, 5 mL dropper vial for prick (skin) testing 22840-0213-2 10,000 BAU/mL, 10 mL multiple-dose vials 22840-0213-4 10,000 BAU/mL, 50 mL multiple-dose vials 22840-0214-5 100,000 BAU/mL, 5 mL dropper vial for prick (skin)… [Excerpted — this section continues on DailyMed.]
📋 Description ▾
11 DESCRIPTION Standardized Grass Pollen Allergenic Extracts include Standardized Bermuda Grass Pollen ( Cynodon dactylon ) at 10,000 BAU/milliliter, 50% glycerin volume/volume, and 0.4% phenol (preservative); and the following grasses at both 10,000 BAU/milliliter and 100,000 BAU/milliliter, 50% glycerin volume/volume, and 0.4% phenol: Standardized Kentucky Blue (June) Grass Pollen ( Poa pratensis ), Standardized Meadow Fescue Grass Pollen ( Festuca elatior ), Standardized Orchard Grass Pollen ( Dactylis glomerata ), Standardized Perennial Rye Grass Pollen ( Lolium perenne ), Standardized Redtop Grass Pollen ( Agrostis alba ), Standardized Sweet Vernal Grass Pollen ( Anthoxanthum odoratum ), and Standardized Timothy Grass Pollen ( Phleum pratense ).
Inactive ingredients include 0.25% sodium chloride for isotonicity and 0.25% sodium bicarbonate as a buffer. Standardized Grass Pollen Allergenic Extracts should be clear light yellow to brownish solutions that are free of particulate matter. Standardized Grass Pollen Allergenic Extracts are labeled in BAU/milliliter.
Bioequivalent Allergy Units are assigned based on comparison by enzyme-linked immunosorbent assay (ELISA) to references from the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). CBER references are assigned unitage based on quantitative skin testing.
4,5,6,7 CBER references which can be diluted 1:5,000,000 to intradermally elicit a 50 millimeter sum of erythema diameter response in highly puncture reactive subjects are assigned 100,000 BAU/milliliter; whereas references diluted 1:500,000 which elicit the same 50 millimeter sum of erythema diameter response are assigned 10,000 BAU/milliliter.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES Specific immunotherapy with pollen extracts is helpful in reducing symptoms associated with exposure to the offending allergens. A summary of effectiveness by the Panel on Review of Allergenic Extracts, an advisory committee to the U.S. Food and Drug Administration, has been published. 8
📚 References ▾
15 REFERENCES Cox L, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol .
2011:S1-S55. Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter.
Ann Allergy Asthma Immunol . 2008;100:S1-148. Greenberg MA, Kaufman CR, Gonzalez GE, et al.
Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol . 1986;77:865-870.
Turkeltaub PC, Rastogi SC, Baer H, et al. A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol .
1982; 70:343-352. ELISA competition assay. Methods of the Allergenic Products Testing Laboratory.
Rockville, MD: Laboratory of Immunobiochemistry, Division of Allergenic Products and Parasitology, Center for Biologics Evaluation and Research, Food and Drug Administration; October 1993. (On file) Turkeltaub PC, Rastogi SC. Quantitative intradermal procedure for evaluation of subject sensitivity to standardized allergenic extracts and for assignment of bioequivalent allergy units to reference preparations using the ID50EAL method.
Rockville, MD: Laboratory of Immunobiochemistry, Division of Allergenic Products and Parasitology, Center for Biologics Evaluation and Research, Food and Drug Administration; November 1994. (On file) Turkeltaub PC. Assignment of bioequivalent allergy units based on biological standardization methods.
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M . 1988;(82):19-40. Implementation of Efficacy Review, Allergenic Extracts, Federal Register 1985; 50: 3082-3288.
📄 Package Label / Principal Display Panel ▾
0200-4_Bermuda_10000-bau 0201-2_Kentucky_Blue_June_10000-bau 0202-5_Kentucky_Blue_June_100000-bau 0203-2_Meadow_Fescue_10000-bau 0204-4_Meadow_Fescue_100000-bau 0205-5_Orchard_10000-bau 0206-2_Orchard_100000-bau 0207-4_Redtop_10000-bau 0208-2_Redtop_100000-bau 0209-5_Perennial_Rye_10000-bau 0210-4_Perennial_Rye_Grass_100000-bau 0211-5_Sweet_Vernal_10000-bau 0212-4_Sweet_Vernal_Grass_100000-bau 0213-2_Timothy_10000-bau 0214-4_Timothy_100000-bau 0215-5_Timothy-Orchard_Grass_100000-bau 0216-2_KOT_Grass_10000-bau 0217-4_KOT_Grass_100000-bau 0218-5_KORT_Grass_10000-bau 0219-2_KORT_Grass_100000-bau 0220-4_KORT-SV_Grass_10000-bau 0221-2_KORT-SV_Grass_100000-bau 0222-5_7_Grass_10000-bau 0223-4_7_Grass_100000-bau 0224-5_TOS Grass_10000-bau 0226-2_Timothy-Orchard_Grass_10000-bau 0227-5_TOS Grass_100000-bau 0225-2_9 Southern Grass Mix_Conc 0225-4_9 Southern Grass Mix_Conc 0225-5_9 Southern Grass Mix_Conc
Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |